Rifaximin Therapy effective against Metronidazole-resistant Clostridium difficile Infection

In a new study conducted by Muhammad Waqas and team it was found that in more than 65 percent of instances, rifaximin medication is beneficial for patients with Clostridium difficile infection (CDI) who are resistant to metronidazole. The findings of this study were published in Cureus Journal.

Infection with Clostridium difficile is a major cause of hospital-acquired diarrhea. Rifaximin is an antibiotic with limited resistance to Clostridium difficile bacteria. The purpose of this study was to determine the effectiveness of rifaximin in metronidazole-resistant CDI patients.

A cross-sectional study was conducted at the Lahore General Hospital in Lahore, Pakistan, from August 2019 to May 2020. A total of 200 instances were included in the study. Patients with CDI had diarrhea after seven days of treatment and a positive C. difficile toxin stool test as identified by the enzyme immunoassay. Only individuals who had not responded to metronidazole medication were included in our study. There were two groups created. For ten days, the intervention group was given 200 mg rifaximin pills three times a day. No new therapy was initiated for patients in the control group. The effectiveness of rifaximin was determined by the absence of diarrhea after two weeks of treatment and a negative stool test.